Business Context and Reporting Period
Company: Sarepta Therapeutics, Inc. (SRPT)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Sarepta is a commercial-stage biopharmaceutical company focused on RNA-targeted therapeutics and gene therapies for rare diseases, primarily Duchenne muscular dystrophy (DMD). The company commercializes four FDA-approved products: EXONDYS 51, VYONDYS 53, AMONDYS 45 (collectively "PMO Products"), and ELEVIDYS (a gene therapy). In February 2025, the company entered into a major collaboration with Arrowhead Pharmaceuticals.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 Value | 2023 Value | Change |
|---|---|---|---|
| Total Revenues | $1,902.0 million | $1,243.3 million | +53% |
| Net Product Revenues | $1,788.0 million | $1,144.9 million | +56% |
| Operating Income | $218.1 million | ($267.8 million) Loss | Turnaround |
| Net Income | $235.2 million | ($536.0 million) Loss | Turnaround |
| Diluted EPS | $2.34 | ($5.80) | N/A |
| Cash & Investments | $1,503.5 million | $1,691.8 million | -11% |
| Long-Term Debt | $1,137.1 million | $1,238.0 million | -8% |
Note: The company achieved its first full-year net income in 2024, reversing a significant loss in 2023.
Material Changes vs. Prior Period
- Revenue Growth: Driven primarily by ELEVIDYS, which generated $820.8 million in revenue (up $620.4 million from 2023) following its expanded FDA approval in June 2024. PMO product revenues remained relatively flat at $967.2 million.
- Profitability: The company transitioned from an operating loss of $267.8 million in 2023 to an operating income of $218.1 million in 2024. This was aided by revenue growth and a reduction in Research and Development (R&D) expenses.
- R&D Expenses: Decreased by 8% to $804.5 million. This reduction was due to the capitalization of commercial batches of ELEVIDYS, the discontinuation of the PPMO platform, and a ramp-down of certain clinical studies, partially offset by costs related to the termination of a manufacturing agreement with Thermo Fisher.
- Cost of Sales: Increased by 112% to $319.1 million, primarily due to higher inventory costs associated with increased ELEVIDYS demand and write-offs of batches not meeting quality specifications.
- Debt Structure: The 2024 Convertible Notes matured and were converted to equity in November 2024. The company currently holds $1.15 billion in 2027 Convertible Notes.
Guidance, Outlook, and Risks
- Strategic Partnership: In February 2025, Sarepta closed a collaboration with Arrowhead Pharmaceuticals, paying a $500 million upfront fee and investing $325 million in Arrowhead stock. This grants Sarepta exclusive global rights to multiple clinical and pre-clinical programs for rare genetic diseases. The company expects to record $500–$600 million in R&D expense in Q1 2025 related to this deal.
- Manufacturing: The company terminated its manufacturing agreement with Thermo Fisher in August 2024, incurring a $55.4 million charge. It relies on Catalent for ELEVIDYS manufacturing and has secured capacity through 2028.
- Regulatory Risks: Several products (EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS for non-ambulatory patients) hold accelerated FDA approvals. Continued approval is contingent upon verifying clinical benefit in confirmatory trials. Failure to meet these post-marketing commitments could result in withdrawal of approval.
- Competition: The company faces competition from Nippon Shinyaku (Viltepso) and other developers of exon-skipping and gene therapies. A patent infringement lawsuit with Nippon Shinyaku concluded in early 2025 with a jury awarding Sarepta approximately $115.2 million in damages.
- Liquidity: Management believes current cash and investments ($1.5 billion) are sufficient to fund operations for at least the next 12 months. A new $600 million revolving credit facility was secured in February 2025.
Investor Verification Checklist
- Confirmatory Trial Data: Monitor upcoming data releases for ELEVIDYS and PMO products required to maintain accelerated FDA approvals.
- Arrowhead Integration: Verify the impact of the $825 million Arrowhead transaction on Q1 2025 earnings and the progress of the acquired clinical programs.
- Manufacturing Capacity: Assess the stability of the supply chain for ELEVIDYS following the Thermo Fisher termination and reliance on Catalent.
- Patent Litigation: Track the status of the appeal regarding the Regenx/U-Penn patent infringement case and the outcome of the Nippon Shinyaku damages collection.
- Reimbursement Trends: Evaluate payer coverage rates and pricing pressures for ELEVIDYS, given its high cost and gene therapy status.